198 related articles for article (PubMed ID: 22545098)
1. Modulation of the activity of Sp transcription factors by mithramycin analogues as a new strategy for treatment of metastatic prostate cancer.
Malek A; Núñez LE; Magistri M; Brambilla L; Jovic S; Carbone GM; Morís F; Catapano CV
PLoS One; 2012; 7(4):e35130. PubMed ID: 22545098
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of Sp1-dependent transcription and antitumor activity of the new aureolic acid analogues mithramycin SDK and SK in human ovarian cancer xenografts.
Previdi S; Malek A; Albertini V; Riva C; Capella C; Broggini M; Carbone GM; Rohr J; Catapano CV
Gynecol Oncol; 2010 Aug; 118(2):182-8. PubMed ID: 20452660
[TBL] [Abstract][Full Text] [Related]
3. Novel GC-rich DNA-binding compound produced by a genetically engineered mutant of the mithramycin producer Streptomyces argillaceus exhibits improved transcriptional repressor activity: implications for cancer therapy.
Albertini V; Jain A; Vignati S; Napoli S; Rinaldi A; Kwee I; Nur-e-Alam M; Bergant J; Bertoni F; Carbone GM; Rohr J; Catapano CV
Nucleic Acids Res; 2006; 34(6):1721-34. PubMed ID: 16571899
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of c-src transcription by mithramycin: structure-activity relationships of biosynthetically produced mithramycin analogues using the c-src promoter as target.
Remsing LL; Bahadori HR; Carbone GM; McGuffie EM; Catapano CV; Rohr J
Biochemistry; 2003 Jul; 42(27):8313-24. PubMed ID: 12846580
[TBL] [Abstract][Full Text] [Related]
5. Nanoparticulate formulations of mithramycin analogs for enhanced cytotoxicity.
Scott D; Rohr J; Bae Y
Int J Nanomedicine; 2011; 6():2757-67. PubMed ID: 22114504
[TBL] [Abstract][Full Text] [Related]
6. Induction of the transcriptional repressor ZBTB4 in prostate cancer cells by drug-induced targeting of microRNA-17-92/106b-25 clusters.
Kim K; Chadalapaka G; Pathi SS; Jin UH; Lee JS; Park YY; Cho SG; Chintharlapalli S; Safe S
Mol Cancer Ther; 2012 Sep; 11(9):1852-62. PubMed ID: 22752225
[TBL] [Abstract][Full Text] [Related]
7. Mithramycin SK, a novel antitumor drug with improved therapeutic index, mithramycin SA, and demycarosyl-mithramycin SK: three new products generated in the mithramycin producer Streptomyces argillaceus through combinatorial biosynthesis.
Remsing LL; González AM; Nur-e-Alam M; Fernández-Lozano MJ; Braña AF; Rix U; Oliveira MA; Méndez C; Salas JA; Rohr J
J Am Chem Soc; 2003 May; 125(19):5745-53. PubMed ID: 12733914
[TBL] [Abstract][Full Text] [Related]
8. The activity of a novel mithramycin analog is related to its binding to DNA, cellular accumulation, and inhibition of Sp1-driven gene transcription.
Fernández-Guizán A; Mansilla S; Barceló F; Vizcaíno C; Núñez LE; Morís F; González S; Portugal J
Chem Biol Interact; 2014 Aug; 219():123-32. PubMed ID: 24907531
[TBL] [Abstract][Full Text] [Related]
9. Transcriptional Reprogramming and Inhibition of Tumor-propagating Stem-like Cells by EC-8042 in ERG-positive Prostate Cancer.
Shinde D; Albino D; Zoma M; Mutti A; Mapelli SN; Civenni G; Kokanovic A; Merulla J; Perez-Escuredo J; Costales P; Morìs F; Catapano CV; Carbone GM
Eur Urol Oncol; 2019 Jul; 2(4):415-424. PubMed ID: 31277777
[TBL] [Abstract][Full Text] [Related]
10. Betulinic acid inhibits colon cancer cell and tumor growth and induces proteasome-dependent and -independent downregulation of specificity proteins (Sp) transcription factors.
Chintharlapalli S; Papineni S; Lei P; Pathi S; Safe S
BMC Cancer; 2011 Aug; 11():371. PubMed ID: 21864401
[TBL] [Abstract][Full Text] [Related]
11. Mithramycin, an agent for developing new therapeutic drugs for neurodegenerative diseases.
Osada N; Kosuge Y; Ishige K; Ito Y
J Pharmacol Sci; 2013; 122(4):251-6. PubMed ID: 23902990
[TBL] [Abstract][Full Text] [Related]
12. Semi-synthetic mithramycin SA derivatives with improved anticancer activity.
Scott D; Chen JM; Bae Y; Rohr J
Chem Biol Drug Des; 2013 May; 81(5):615-24. PubMed ID: 23331575
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of SP1 by the mithramycin analog EC-8042 efficiently targets tumor initiating cells in sarcoma.
Tornin J; Martinez-Cruzado L; Santos L; Rodriguez A; Núñez LE; Oro P; Hermosilla MA; Allonca E; Fernández-García MT; Astudillo A; Suarez C; Morís F; Rodriguez R
Oncotarget; 2016 May; 7(21):30935-50. PubMed ID: 27105533
[TBL] [Abstract][Full Text] [Related]
14. Dimerization and DNA recognition rules of mithramycin and its analogues.
Weidenbach S; Hou C; Chen JM; Tsodikov OV; Rohr J
J Inorg Biochem; 2016 Mar; 156():40-7. PubMed ID: 26760230
[TBL] [Abstract][Full Text] [Related]
15. Mithramycin delivery systems to develop effective therapies in sarcomas.
Estupiñán Ó; Niza E; Bravo I; Rey V; Tornín J; Gallego B; Clemente-Casares P; Moris F; Ocaña A; Blanco-Lorenzo V; Rodríguez-Santamaría M; Vallina-Álvarez A; González MV; Rodríguez A; Hermida-Merino D; Alonso-Moreno C; Rodríguez R
J Nanobiotechnology; 2021 Sep; 19(1):267. PubMed ID: 34488783
[TBL] [Abstract][Full Text] [Related]
16. Modulation of specificity protein 1 by mithramycin A as a novel therapeutic strategy for cervical cancer.
Choi ES; Nam JS; Jung JY; Cho NP; Cho SD
Sci Rep; 2014 Nov; 4():7162. PubMed ID: 25418289
[TBL] [Abstract][Full Text] [Related]
17. The antitumor antibiotic mithramycin: new advanced approaches in modification and production.
Kormanec J; Novakova R; Csolleiova D; Feckova L; Rezuchova B; Sevcikova B; Homerova D
Appl Microbiol Biotechnol; 2020 Sep; 104(18):7701-7721. PubMed ID: 32686008
[TBL] [Abstract][Full Text] [Related]
18. Mithramycin analogues generated by combinatorial biosynthesis show improved bioactivity.
Baig I; Perez M; Braña AF; Gomathinayagam R; Damodaran C; Salas JA; Méndez C; Rohr J
J Nat Prod; 2008 Feb; 71(2):199-207. PubMed ID: 18197601
[TBL] [Abstract][Full Text] [Related]
19. Differential inhibition of restriction enzyme cleavage by chromophore-modified analogues of the antitumour antibiotics mithramycin and chromomycin reveals structure-activity relationships.
Mansilla S; Garcia-Ferrer I; Méndez C; Salas JA; Portugal J
Biochem Pharmacol; 2010 May; 79(10):1418-27. PubMed ID: 20093108
[TBL] [Abstract][Full Text] [Related]
20. Mithramycin 2'-Oximes with Improved Selectivity, Pharmacokinetics, and Ewing Sarcoma Antitumor Efficacy.
Liu Y; Eckenrode JM; Zhang Y; Zhang J; Hayden RC; Kyomuhangi A; Ponomareva LV; Cui Z; Rohr J; Tsodikov OV; Van Lanen SG; Shaaban KA; Leggas M; Thorson JS
J Med Chem; 2020 Nov; 63(22):14067-14086. PubMed ID: 33191745
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
